The Experts below are selected from a list of 687 Experts worldwide ranked by ideXlab platform
Fumio Nomura - One of the best experts on this subject based on the ideXlab platform.
-
Serum Periplakin as a potential biomarker for urothelial carcinoma of the urinary bladder.
Asian Pacific Journal of Cancer Prevention, 2014Co-Authors: Kazumasa Matsumoto, Masaomi Ikeda, Yuichi Sato, Takanori Nishimori, Fumio Nomura, Toshihide Matsumoto, Ryo Nagashio, Hidero Kitasato, Takeshi Tomonaga, Masatsugu IwamuraAbstract:The objectives of this study were to examine serum Periplakin expression in patients with urothelial carcinoma of the urinary bladder and in normal controls, and to examine relationships with clinicopathological findings. Detection of serum Periplakin was performed in 50 patients and 30 normal controls with anti-Periplakin antibodies using the automatic dot blot system, and a micro-dot blot array with a 256 solid-pin system. Levels in patients with urothelial carcinoma of the urinary bladder were significantly lower than those in normal controls (0.31 and 5.68, respectively; p
-
loss of Periplakin expression is associated with pathological stage and cancerspecific survival in patients with urothelial carcinoma of the urinary bladder
Biomedical Research-tokyo, 2014Co-Authors: Kazumasa Matsumoto, Masaomi Ikeda, Yuichi Sato, Hidetoshi Kuruma, Yuko Kamata, Takanori Nishimori, Tsuyoshi Tomonaga, Fumio Nomura, Shin Egawa, Masatsugu IwamuraAbstract:: The objective of this study was to determine Periplakin expression in normal urothelium and bladder cancer tissues and the relationship to clinicopathological findings. Immunohistochemical staining for Periplakin was carried out in 92 archival radical cystectomy specimens, with immunoreactivity being stratified on a 0-6 scale. Immunohistochemical staining for Periplakin was shown to be significantly lower in bladder cancer tissues compared to non-cancerous tissues including inflammation,hyperplasia and normal urothelium. Loss of Periplakin expression was associated with pathological stage (P=0.04). In multivariate Cox regression analysis, loss of Periplakin expression and positive lymph node status were independent prognostic factors for cancer-specific survival (P=0.03 and 0.015; odds ratio=2.29 and 2.66; 95% confidence interval=1.085-4.814 and 1.214-5.845, respectively). This new molecular marker may aid in identifying and selecting bladder cancer patients undergoing radical cystectomy who may potentially benefit from neoadjuvant or adjuvant therapy.
-
serum Periplakin as a potential biomarker for urothelial carcinoma of the urinary bladder
Asian Pacific Journal of Cancer Prevention, 2014Co-Authors: Kazumasa Matsumoto, Masaomi Ikeda, Yuichi Sato, Takanori Nishimori, Tsuyoshi Tomonaga, Fumio Nomura, Toshihide Matsumoto, Ryo Nagashio, Hidero Kitasato, Masatsugu IwamuraAbstract:The objectives of this study were to examine serum Periplakin expression in patients with urothelial carcinoma of the urinary bladder and in normal controls, and to examine relationships with clinicopathological findings. Detection of serum Periplakin was performed in 50 patients and 30 normal controls with anti-Periplakin antibodies using the automatic dot blot system, and a micro-dot blot array with a 256 solid-pin system. Levels in patients with urothelial carcinoma of the urinary bladder were significantly lower than those in normal controls (0.31 and 5.68, respectively; p<0.0001). The area under the receiver-operator curve level for urothelial carcinoma of the urinary bladder was 0.845. The sensitivity and specificity, using a cut-off point of 4.045, were 83.7% and 73.3%, respectively. In addition, serum Periplakin levels were significantly higher in patients with muscle-invasive cancer than in those with nonmuscle-invasive cancer (P = 0.03). In multivariate Cox proportional hazards regression analysis, none of the clinicopathological factors was associated with an increased risk for progression and cancer-specific survival. Examination of the serum Periplakin level may play a role as a noninvasive diagnostic modality to aid urine cytology and cystoscopy.
-
adhesion molecule Periplakin is involved in cellular movement and attachment in pharyngeal squamous cancer cells
BMC Cell Biology, 2011Co-Authors: Yurie Tonoike, Takeshi Tomonaga, Kazuyuki Matsushita, Hideaki Shimada, Koji Katada, Nobuko Tanaka, Yukio Nakatani, Yoshitaka Okamoto, Fumio NomuraAbstract:We previously reported that Periplakin (PPL) is downregulated in human esophageal cancer tissues compared to the adjacent non-cancer epithelium. Thus PPL could be a useful marker for detection of early esophageal cancer and evaluation of tumor progression, but largely remains unknown in this field. To investigate PPL involvement in carcinogenesis, tumor progression, cellular movement or attachment activity, siRNAs against PPL were transfected into pharyngeal squamous cancer cell lines and their effects on cellular behaviours were examined. PPL knockdown appeared to decrease tumor cell growth together with G2/M phase accumulation in cells attached to a culture dish. However, the extent of cell growth suppression, evaluated by the number of cells attached to the culture dish, was too distinctive to be explained only by cell cycle delay. Importantly, PPL knockdown suppressed cellular movement and attachment to the culture dish accompanied by decreased pAktSer473 phosphorylation. Additionally, LY294002, a PI3K inhibitor that dephosphorylates pAktSer473, significantly suppressed D562 cell migration. Thus PPL potentially engages in cellular movement al least partly via the PI3K/Akt axis. PPL knockdown is related to reduced cellular movement and attachment activity in association with PI3K/Akt axis suppression, rather than malignant progression in pharyngeal cancer cells.
-
proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein Periplakin
Proteomics, 2006Co-Authors: Takanori Nishimori, Fumio Nomura, Takeshi Tomonaga, Kazuyuki Matsushita, Masamichi Ohishi, Yoshio Kodera, Tadakazu Maeda, Hisahiro Matsubara, Hideaki Shimada, Takenori OchiaiAbstract:Recent advances in two-dimensional electrophoresis (2-DE) such as fluorescent 2-D differential gel electrophoresis (2-D DIGE) has made it possible to detect and quantitate the critical changes involved in disease pathogenesis. We have previously identified novel proteins with altered expression in primary colorectal cancer using agarose 2-DE that has a higher loading capacity than immobilized pH gradient gel. The aim of this study is to identify novel proteins with altered expression in primary esophageal cancer using the powerful method of agarose 2-DE and agarose 2-D DIGE. Excised tissues from 12 patients of primary esophageal cancer were obtained. Proteins with altered expression between cancer and adjacent non-cancer tissues were analyzed by agarose 2-D DIGE and identified by mass spectrometry. Thirty-three proteins out of 74 spots with altered expression in tumors were identified. Among them, a 195-kDa protein, Periplakin, was significantly downregulated in esophageal cancer, which was confirmed by immunoblotting. Immunohistochemistry showed that Periplakin was mainly localized at cell-cell boundaries in normal epithelium and dysplastic lesions, while it disappeared from cell boundaries, shifted to cytoplasm, in early cancers and scarcely expressed in advanced cancers. These results suggest that Periplakin could be a useful marker for detection of early esophageal cancer and evaluation of tumor progression.
Takashi Hashimoto - One of the best experts on this subject based on the ideXlab platform.
-
Bullous Pemphigoid Associated with Ischemic Cerebrovascular Accident and Dementia: Exclusive Blistering Lesions on the Upper Hemiparetic Limb.
Acta Dermatovenerologica Croatica, 2018Co-Authors: Sebastian Vernal, Norito Ishii, Takashi Hashimoto, Tamiris Julio, Fernanda Aguiar Da Cruz, Ana Maria Ferreira RoselinoAbstract:Bullous pemphigoid (BP) has been associated with neurological disorders (NDs), which has led to the hypothesis that molecular mimicry exists between hemidesmosomal proteins and neuronal peptides. A 79-year-old hemiparetic woman presented with tense bullae affecting exclusively her right paretic upper limb for three months. Histopathology, taken from the perilesional area, revealed an inflammatory infiltrate with predominant eosinophils. IIF evidenced linear IgG deposition in the epidermal side of the cleavage. ELISA detected circulating anti-BP180 and anti-BP230 autoantibodies. Immunoblotting exhibited unspecific reactivity against the 190-kDa Periplakin in normal human epidermal extract. The immunocompromised cutaneous district concept may explain the possible mechanism for the exclusive involvement of the autoimmune blistering disease in lymphedematous hemiparetic upper limb.
-
Paraneoplastic Pemphigus Associated with a Malignant Thymoma: A Case of Persistent and Refractory Oral Ulcerations Following Thymectomy.
Annals of Dermatology, 2017Co-Authors: Takashi HashimotoAbstract:: Paraneoplastic pemphigus is a rare, life-threatening autoimmune mucocutaneous blistering disease associated with underlying neoplasia, commonly lymphoproliferative tumors. Herein we report a case of paraneoplastic pemphigus with a unique autoantibody profile associated with a malignant thymoma. A 56-year-old female patient presented with relapsing oral ulcerations accompanied by erythematous papules and patches on her extremities for 2 months. Skin and mucosal biopsies identified interface dermatitis with lichenoid lymphocytic infiltration in the upper dermis. Immunoblotting and enzyme-linked immunosorbent assays revealed that the patient had multiple autoantibodies against desmoglein 1, desmocollin 1, 2, 3, laminin gamma-1, envoplakin, and Periplakin. The skin lesions completely healed following thymectomy and systemic corticosteroid therapy, but the oral ulcerations persisted through a follow-up period of over 2 years.
-
Case of paraneoplastic pemphigus with immunoglobulin (Ig)G and IgA antibodies to various antigens.
Journal of Dermatology, 2016Co-Authors: Yohei Otsuka, Norito Ishii, Takashi Ueno, Aya Yamase, Shin-ichi Osada, Seiji Kawana, Yoko Funasaka, Kwesi Teye, Takashi HashimotoAbstract:A 63-year-old Japanese man with non-Hodgkin B-cell lymphoma presented with erythematous skin lesions on his entire body, with oral, ocular and anal mucosal lesions. The patient was diagnosed with paraneoplastic pemphigus. Immunofluorescence showed both immunoglobulin (Ig)G and IgA antibodies to keratinocyte cell surfaces. Various immunoblot and enzyme-linked immunosorbent assays showed both IgG and IgA antibodies to various autoantigens, including desmogleins, desmocollins, envoplakin, Periplakin and bullous pemphigoid antigens. This was a unique case with a very rare autoantibody profile in paraneoplastic pemphigus.
-
detection of autoantibodies to Periplakin and envoplakin in paraneoplastic pemphigus but not idiopathic pulmonary fibrosis using full length recombinant proteins
Clinica Chimica Acta, 2014Co-Authors: Yoshinao Muro, Kazumitsu Sugiura, Akira Shiraki, Norito Ishii, Takashi Hashimoto, Masashi AkiyamaAbstract:Abstract Background Paraneoplastic pemphigus (PNP) serum preferentially reacts with Periplakin and envoplakin, which are plakin family proteins localized to desmosomes and intermediate filaments. Recently, anti-Periplakin antibodies were also detected in patients with idiopathic pulmonary fibrosis (IPF). Although previous epitope-mapping studies showed multiple epitopes in each protein, enzyme-linked immunosorbent assays have used several truncated, but not full-length, recombinant proteins. Methods This study aimed to produce full-length biotinylated recombinant proteins of Periplakin and envoplakin for detection of autoantibodies by immunoprecipitation and ELISA. Serum from a PNP patient who had been confirmed as carrying anti-Periplakin and anti-envoplakin antibodies in our previous study was used as a positive control. Sera from 15 patients with IPF were analyzed for both antibodies by immunoprecipitation and by ELISA. Results The PNP serum reacted strongly with the full-length recombinant proteins in immunoprecipitation and ELISA. Longitudinal serum samples from the PNP patient showed a clear decline of autoantibodies to both Periplakin and envoplakin. None of the IPF sera showed both autoantibodies. Conclusions We found that the detection of anti-Periplakin and anti-envoplakin antibodies using full-length recombinant proteins is useful immunoprecipitation and ELISA.
-
Clinical and immunologic characterization in 26 Indian pemphigus patients.
Journal of Cutaneous Medicine and Surgery, 2013Co-Authors: Daisuke Tsuruta, Norito Ishii, Amrinder J Kanwar, Keshavamurthy Vinay, Shunpei Fukuda, Hiroshi Koga, Teruki Dainichi, Chika Ohata, Takashi HashimotoAbstract:BACKGROUND: Pemphigus shows geographically variable characteristics. OBJECTIVE: To study the clinical and immunologic characteristics of Indian pemphigus patients before and after treatment. METHODS: Twenty-six Indian pemphigus patients were analyzed with regard to age, gender, clinical features, treatments and response, the results of histopathology, direct and indirect immunofluorescence (IF), enzyme-linked immunosorbent assay (ELISA), and immunoblot analyses. RESULTS: There were 22 pemphigus vulgaris (PV) and 4 pemphigus foliaceus (PF) patients. Direct and indirect IF was positive in 95.8% and 56% of patients, respectively. Indices of ELISA were lower in our study. Immunoblot assays detected the 130 kDa desmoglein-3 in 10 PV patients and the 160 kDa desmoglein-1 in 1 PV patient; 190 kDa Periplakin was unexpectedly detected in 8 patients. CONCLUSION: Indian pemphigus patients showed several unique characteristics, including younger population, predominance of PV, low ELISA indices, lower sensitivity of indirect IF and immunoblotting, and the presence of the 190 kDa Periplakin in nearly one-third of patients.
Jouni Uitto - One of the best experts on this subject based on the ideXlab platform.
-
mice deficient in involucrin envoplakin and Periplakin have a defective epidermal barrier
Journal of Cell Biology, 2007Co-Authors: Lisa M Sevilla, Arto Määttä, Jouni Uitto, John F Klement, Rachida Nachat, Karen R. Groot, Philippe Djian, Fiona M WattAbstract:The cornified envelope is assembled from transglutaminase cross-linked proteins and lipids in the outermost epidermal layers and is essential for skin barrier function. Involucrin, envoplakin, and Periplakin form the protein scaffold on which the envelope assembles. To examine their combined function, we generated mice deficient in all three genes. The triple knockouts have delayed embryonic barrier formation and postnatal hyperkeratosis (abnormal accumulation of cornified cells) resulting from impaired desquamation. Cornified envelopes form but are ultrastructurally abnormal, with reduced lipid content and decreased mechanical integrity. Expression of proteases is reduced and the protease inhibitor, serpina1b, is highly upregulated, resulting in defective filaggrin processing and delayed degradation of desmoglein 1 and corneodesmosin. There is infiltration of CD4+ T cells and a reduction in resident γδ+ T cells, reminiscent of atopic dermatitis. Thus, combined loss of the cornified envelope proteins not only impairs the epidermal barrier, but also changes the composition of T cell subpopulations in the skin.
-
breaking the connection caspase 6 disconnects intermediate filament binding domain of Periplakin from its actin binding n terminal region
Journal of Investigative Dermatology, 2005Co-Authors: Andrey E Kalinin, Alexandr Kalinin, Jouni UittoAbstract:Periplakin is a member of the plakin family of cytolinkers that connect cytoskeletal networks to each other as well as to the cell junctional complexes. Here, we demonstrate a direct molecular interaction between actin and Periplakin. Furthermore, the oligomerization state of Periplakin was shown to determine specificity of its binding to intermediate filaments (IF) in vitro. Both the filament association and the cell membrane localization of Periplakin were confirmed in the cells overexpressing human Periplakin. Double labeling of the N- and C-terminally tagged Periplakin revealed unexpected lack of co-localization of Periplakin ends in a confluent culture, and separation of the Periplakin ends was even more pronounced in apoptotic cells. Western analysis revealed that after induction of apoptosis, Periplakin becomes cleaved close to its C-terminal tail. Only the distinct cleavage products, but not the full-length Periplakin, were present in the cells detached from the solid support during the apoptotic process. We show that caspase 6 cleaves Periplakin at an unconventional recognition site, amino acid sequence TVAD. Thus, the separation of Periplakin ends disconnects the actin-binding head-rod domain from the IF-binding C-terminal domain. We show that specific cleavage products co-exist with the full-length Periplakin in cells, suggesting physiological consequences due to their altered binding specificities.
-
Periplakin gene targeting reveals a constituent of the cornified cell envelope dispensable for normal mouse development
Molecular and Cellular Biology, 2004Co-Authors: Kehua Li, Jouni Uitto, Young W Ryoo, Clair Mcgee, Akemi Ishidayamamoto, John F KlementAbstract:The members of the plakin family of proteins serve as epidermal cytolinkers and components of cell-cell and cell-matrix adhesion complexes, i.e., desmosomes and hemidesmosomes, respectively. Periplakin is a recently characterized member of this family. Human and mouse Periplakin genomic loci are conserved, and the proteins are highly homologous, suggesting a role for Periplakin in vertebrate physiology. In order to evaluate the functional role of Periplakin, we generated Periplakin null mice through targeted homologous recombination of mouse embryonic stem cells, followed by development of Ppl−/− mice. Mice homozygous for the targeted allele were born in the expected Mendelian frequency, developed normally, possessed grossly normal epidermis and hair, and were healthy and fertile. The epidermal barrier appeared to develop normally during fetal days E15.5 to E16.5, and the cornified envelope and desmosomes in the newborn mice were ultrastructurally normal. No compensatory increase in the expression of other epithelial proteins was detected in the neonatal mouse epidermis lacking Periplakin. Consequently, the primary role of Periplakin may not relate to the physiology of the cornified cell envelope in epidermal keratinocytes but may reside in the challenges, which normal laboratory mice do not encounter.
-
unique role for the Periplakin tail in intermediate filament association specific binding to keratin 8 and vimentin
Experimental Dermatology, 2002Co-Authors: Shideh Kazerounian, Jouni UittoAbstract:: Plectin, desmoplakin, and the 230-kDa bullous pemphigoid antigen (BPAG1), members of the plakin family of proteins, are multifunctional cytolinkers, connecting the cytoskeletal structures to the cell adhesion complexes. Envoplakin and Periplakin are components of the cornified envelope, but less is known about their role in tissues other than the stratified epithelium. Our tissue-wide survey utilizing RT-PCR revealed that Periplakin, like plectin and desmoplakin, has a wide tissue distribution, but envoplakin expression is limited to certain tissues only, and BPAG1 is clearly specific for epidermal keratinocytes. Plectin, desmoplakin and BPAG1 are known to bind to the intermediate filaments through their C-terminal domains. The short C-terminal domain of Periplakin is composed only of the linker domain, a region highly homologous between the plakin proteins. Here we demonstrate, through the use of yeast two-hybrid assay, a specific interaction of the Periplakin linker domain with keratin 8 and vimentin. Co-expression of each plakin linker domain with keratin 8 revealed that Periplakin and BPAG1 linkers co-localize with keratin signals in HaCaT cells, plectin and desmoplakin linkers were detected both in the nucleus and in cytoplasm together with the overexpressed keratin 8, while envoplakin linker localized independently into the nucleus. These results suggest that, in spite of its high homology and structural similarity with envoplakin, Periplakin is functionally closer to the well-characterized plakin proteins plectin and desmoplakin, and thus may function tissue-wide as a scaffolding protein in intermediate filament assembly.
-
human Periplakin genomic organization in a clonally unstable region of chromosome 16p with an abundance of repetitive sequence elements
Genomics, 1999Co-Authors: K Rothenberger, Young W Ryoo, W H I Mclean, Jouni UittoAbstract:Abstract Periplakin, a member of the plakin family of proteins, has been recently characterized by cDNA cloning, and the corresponding gene, PPL, has been mapped to human chromosome 16p13.3 (Aho et al., 1998, Genomics 48: 242–247). Periplakin has also been shown to serve as an autoantigen in a malignancy-associated autoimmune blistering disease, paraneoplastic pemphigus (Mahoney et al., 1998, J. Invest. Dermatol. 111: 308–313). In this study, we have elucidated the intron–exon organization of human PPL and characterized its promoter region. The flanking 5′ sequences were rich in G and C (∼80%) and included multiple AP2 sites and a SP1 site, while no canonical TATA or CCAAT sequences were found. The functionality of the upstream sequences (−709 to +135) as a promoter in cultured epidermal keratinocytes was detected by a CAT reporter gene, and a limited region (−382 to +135) showed activity in cultured dermal fibroblasts, attesting to cell-type specificity of the promoter. The genomic organization, including the intron–exon borders, was determined by direct nucleotide sequencing of human genomic P1 clones. Comparative analysis of cDNA and genomic sequences revealed that PPL consists of 22 exons, with the distribution of exons in PPL being consistent with that of other plakin genes: 21 small exons, separated by large introns, encode the amino-terminal globular domain, and 1 large exon encodes the entire rod and the tail domains. Characterization of four P1 clones spanning the PPL locus revealed multiple Alu repeats, 20 of them within 33 kb of the entirely sequenced segments (0.60/kb), in addition to numerous MIR and L1 elements. These repetitive elements could lead to the clonal instability detected throughout the genomic P1 clones and may give rise to the genomic rearrangements possibly underlying the paraneoplastic pemphigus.
Masatsugu Iwamura - One of the best experts on this subject based on the ideXlab platform.
-
Serum Periplakin as a potential biomarker for urothelial carcinoma of the urinary bladder.
Asian Pacific Journal of Cancer Prevention, 2014Co-Authors: Kazumasa Matsumoto, Masaomi Ikeda, Yuichi Sato, Takanori Nishimori, Fumio Nomura, Toshihide Matsumoto, Ryo Nagashio, Hidero Kitasato, Takeshi Tomonaga, Masatsugu IwamuraAbstract:The objectives of this study were to examine serum Periplakin expression in patients with urothelial carcinoma of the urinary bladder and in normal controls, and to examine relationships with clinicopathological findings. Detection of serum Periplakin was performed in 50 patients and 30 normal controls with anti-Periplakin antibodies using the automatic dot blot system, and a micro-dot blot array with a 256 solid-pin system. Levels in patients with urothelial carcinoma of the urinary bladder were significantly lower than those in normal controls (0.31 and 5.68, respectively; p
-
loss of Periplakin expression is associated with pathological stage and cancerspecific survival in patients with urothelial carcinoma of the urinary bladder
Biomedical Research-tokyo, 2014Co-Authors: Kazumasa Matsumoto, Masaomi Ikeda, Yuichi Sato, Hidetoshi Kuruma, Yuko Kamata, Takanori Nishimori, Tsuyoshi Tomonaga, Fumio Nomura, Shin Egawa, Masatsugu IwamuraAbstract:: The objective of this study was to determine Periplakin expression in normal urothelium and bladder cancer tissues and the relationship to clinicopathological findings. Immunohistochemical staining for Periplakin was carried out in 92 archival radical cystectomy specimens, with immunoreactivity being stratified on a 0-6 scale. Immunohistochemical staining for Periplakin was shown to be significantly lower in bladder cancer tissues compared to non-cancerous tissues including inflammation,hyperplasia and normal urothelium. Loss of Periplakin expression was associated with pathological stage (P=0.04). In multivariate Cox regression analysis, loss of Periplakin expression and positive lymph node status were independent prognostic factors for cancer-specific survival (P=0.03 and 0.015; odds ratio=2.29 and 2.66; 95% confidence interval=1.085-4.814 and 1.214-5.845, respectively). This new molecular marker may aid in identifying and selecting bladder cancer patients undergoing radical cystectomy who may potentially benefit from neoadjuvant or adjuvant therapy.
-
serum Periplakin as a potential biomarker for urothelial carcinoma of the urinary bladder
Asian Pacific Journal of Cancer Prevention, 2014Co-Authors: Kazumasa Matsumoto, Masaomi Ikeda, Yuichi Sato, Takanori Nishimori, Tsuyoshi Tomonaga, Fumio Nomura, Toshihide Matsumoto, Ryo Nagashio, Hidero Kitasato, Masatsugu IwamuraAbstract:The objectives of this study were to examine serum Periplakin expression in patients with urothelial carcinoma of the urinary bladder and in normal controls, and to examine relationships with clinicopathological findings. Detection of serum Periplakin was performed in 50 patients and 30 normal controls with anti-Periplakin antibodies using the automatic dot blot system, and a micro-dot blot array with a 256 solid-pin system. Levels in patients with urothelial carcinoma of the urinary bladder were significantly lower than those in normal controls (0.31 and 5.68, respectively; p<0.0001). The area under the receiver-operator curve level for urothelial carcinoma of the urinary bladder was 0.845. The sensitivity and specificity, using a cut-off point of 4.045, were 83.7% and 73.3%, respectively. In addition, serum Periplakin levels were significantly higher in patients with muscle-invasive cancer than in those with nonmuscle-invasive cancer (P = 0.03). In multivariate Cox proportional hazards regression analysis, none of the clinicopathological factors was associated with an increased risk for progression and cancer-specific survival. Examination of the serum Periplakin level may play a role as a noninvasive diagnostic modality to aid urine cytology and cystoscopy.
Takanori Nishimori - One of the best experts on this subject based on the ideXlab platform.
-
Serum Periplakin as a potential biomarker for urothelial carcinoma of the urinary bladder.
Asian Pacific Journal of Cancer Prevention, 2014Co-Authors: Kazumasa Matsumoto, Masaomi Ikeda, Yuichi Sato, Takanori Nishimori, Fumio Nomura, Toshihide Matsumoto, Ryo Nagashio, Hidero Kitasato, Takeshi Tomonaga, Masatsugu IwamuraAbstract:The objectives of this study were to examine serum Periplakin expression in patients with urothelial carcinoma of the urinary bladder and in normal controls, and to examine relationships with clinicopathological findings. Detection of serum Periplakin was performed in 50 patients and 30 normal controls with anti-Periplakin antibodies using the automatic dot blot system, and a micro-dot blot array with a 256 solid-pin system. Levels in patients with urothelial carcinoma of the urinary bladder were significantly lower than those in normal controls (0.31 and 5.68, respectively; p
-
loss of Periplakin expression is associated with pathological stage and cancerspecific survival in patients with urothelial carcinoma of the urinary bladder
Biomedical Research-tokyo, 2014Co-Authors: Kazumasa Matsumoto, Masaomi Ikeda, Yuichi Sato, Hidetoshi Kuruma, Yuko Kamata, Takanori Nishimori, Tsuyoshi Tomonaga, Fumio Nomura, Shin Egawa, Masatsugu IwamuraAbstract:: The objective of this study was to determine Periplakin expression in normal urothelium and bladder cancer tissues and the relationship to clinicopathological findings. Immunohistochemical staining for Periplakin was carried out in 92 archival radical cystectomy specimens, with immunoreactivity being stratified on a 0-6 scale. Immunohistochemical staining for Periplakin was shown to be significantly lower in bladder cancer tissues compared to non-cancerous tissues including inflammation,hyperplasia and normal urothelium. Loss of Periplakin expression was associated with pathological stage (P=0.04). In multivariate Cox regression analysis, loss of Periplakin expression and positive lymph node status were independent prognostic factors for cancer-specific survival (P=0.03 and 0.015; odds ratio=2.29 and 2.66; 95% confidence interval=1.085-4.814 and 1.214-5.845, respectively). This new molecular marker may aid in identifying and selecting bladder cancer patients undergoing radical cystectomy who may potentially benefit from neoadjuvant or adjuvant therapy.
-
serum Periplakin as a potential biomarker for urothelial carcinoma of the urinary bladder
Asian Pacific Journal of Cancer Prevention, 2014Co-Authors: Kazumasa Matsumoto, Masaomi Ikeda, Yuichi Sato, Takanori Nishimori, Tsuyoshi Tomonaga, Fumio Nomura, Toshihide Matsumoto, Ryo Nagashio, Hidero Kitasato, Masatsugu IwamuraAbstract:The objectives of this study were to examine serum Periplakin expression in patients with urothelial carcinoma of the urinary bladder and in normal controls, and to examine relationships with clinicopathological findings. Detection of serum Periplakin was performed in 50 patients and 30 normal controls with anti-Periplakin antibodies using the automatic dot blot system, and a micro-dot blot array with a 256 solid-pin system. Levels in patients with urothelial carcinoma of the urinary bladder were significantly lower than those in normal controls (0.31 and 5.68, respectively; p<0.0001). The area under the receiver-operator curve level for urothelial carcinoma of the urinary bladder was 0.845. The sensitivity and specificity, using a cut-off point of 4.045, were 83.7% and 73.3%, respectively. In addition, serum Periplakin levels were significantly higher in patients with muscle-invasive cancer than in those with nonmuscle-invasive cancer (P = 0.03). In multivariate Cox proportional hazards regression analysis, none of the clinicopathological factors was associated with an increased risk for progression and cancer-specific survival. Examination of the serum Periplakin level may play a role as a noninvasive diagnostic modality to aid urine cytology and cystoscopy.
-
proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein Periplakin
Proteomics, 2006Co-Authors: Takanori Nishimori, Fumio Nomura, Takeshi Tomonaga, Kazuyuki Matsushita, Masamichi Ohishi, Yoshio Kodera, Tadakazu Maeda, Hisahiro Matsubara, Hideaki Shimada, Takenori OchiaiAbstract:Recent advances in two-dimensional electrophoresis (2-DE) such as fluorescent 2-D differential gel electrophoresis (2-D DIGE) has made it possible to detect and quantitate the critical changes involved in disease pathogenesis. We have previously identified novel proteins with altered expression in primary colorectal cancer using agarose 2-DE that has a higher loading capacity than immobilized pH gradient gel. The aim of this study is to identify novel proteins with altered expression in primary esophageal cancer using the powerful method of agarose 2-DE and agarose 2-D DIGE. Excised tissues from 12 patients of primary esophageal cancer were obtained. Proteins with altered expression between cancer and adjacent non-cancer tissues were analyzed by agarose 2-D DIGE and identified by mass spectrometry. Thirty-three proteins out of 74 spots with altered expression in tumors were identified. Among them, a 195-kDa protein, Periplakin, was significantly downregulated in esophageal cancer, which was confirmed by immunoblotting. Immunohistochemistry showed that Periplakin was mainly localized at cell-cell boundaries in normal epithelium and dysplastic lesions, while it disappeared from cell boundaries, shifted to cytoplasm, in early cancers and scarcely expressed in advanced cancers. These results suggest that Periplakin could be a useful marker for detection of early esophageal cancer and evaluation of tumor progression.